{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:55:10Z","timestamp":1793372110457,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12886-018-0685-6","type":"journal-article","created":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T19:47:08Z","timestamp":1517255228000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP)"],"prefix":"10.1186","volume":"18","author":[{"given":"Zijing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunru","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,30]]},"reference":[{"key":"685_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","volume":"84","author":"C Gilbert","year":"2008","unstructured":"Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008;84:77\u201382.","journal-title":"Early Hum Dev"},{"key":"685_CR2","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment For Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684\u201394.","journal-title":"Arch Ophthalmol"},{"key":"685_CR3","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0161-6420(91)32247-4","volume":"98","author":"MN JA","year":"1991","unstructured":"JA MN, Tasman W, Brown GC, Federman JL. Laser photocoagulation for stage 3+ retinopathy of prematurity. Ophthalmology. 1991;98:576\u201380.","journal-title":"Ophthalmology"},{"key":"685_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0002-9394(98)00284-0","volume":"127","author":"SE Brooks","year":"1999","unstructured":"Brooks SE, Johnson M, Wallace DK, Paysse EA, Coats DK, Marcus DM. Treatment outcome in fellow eyes after laser photocoagulation for retinopathy of prematurity. Am J Ophthalmol. 1999;127:56\u201361.","journal-title":"Am J Ophthalmol"},{"key":"685_CR5","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0161-6420(99)00042-1","volume":"107","author":"MJ Banach","year":"2000","unstructured":"Banach MJ, Ferrone PJ, Trese MT. A comparison of dense versus less dense diode laser photocoagulation patterns for threshold retinopathy of prematurity. Ophthalmology. 2000;107:324\u20137. discussion 328","journal-title":"Ophthalmology"},{"key":"685_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/00055735-200106000-00003","volume":"12","author":"MJ Banach","year":"2001","unstructured":"Banach MJ, Berinstein DM. Laser therapy for retinopathy of prematurity. Curr Opin Ophthalmol. 2001;12:164\u201370.","journal-title":"Curr Opin Ophthalmol"},{"issue":"3","key":"685_CR7","first-page":"365","volume":"101","author":"B Mueller","year":"2017","unstructured":"Mueller B, Salchow DJ, Waffenschmidt E, Joussen AM, Schmalisch G, Czernik C, et al. Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. Br J Ophthalmol. 2017;101(3):365\u201370.","journal-title":"Br J Ophthalmol"},{"key":"685_CR8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jaapos.2015.01.009","volume":"19","author":"M Isaac","year":"2015","unstructured":"Isaac M, Mireskandari K, Tehrani N. Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser. J AAPOS. 2015;19:140\u20134.","journal-title":"J AAPOS."},{"key":"685_CR9","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","volume":"122","author":"CK Hwang","year":"2015","unstructured":"Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after Intravitreal Bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. 2015;122:1008\u201315.","journal-title":"Ophthalmology"},{"issue":"1","key":"685_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/IAE.0000000000001125","volume":"37","author":"JM Yoon","year":"2017","unstructured":"Yoon JM, Shin DH, Kim SJ, Ham DI, Kang SW, Chang YS, et al. Outcomes after laser versus combined laser and Bevacizumab treatment for type 1 retinopathy of prematurity in zone I. Retina. 2017;37(1):88\u201396.","journal-title":"Retina"},{"key":"685_CR11","doi-asserted-by":"crossref","unstructured":"Gunay M, Sukgen EA, Celik G, Kocluk Y. Comparison of Bevacizumab, Ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey. Curr Eye Res. 2017;42(3):462\u20139.","DOI":"10.1080\/02713683.2016.1196709"},{"key":"685_CR12","doi-asserted-by":"publisher","first-page":"e496","DOI":"10.1111\/aos.12339","volume":"92","author":"S Moran","year":"2014","unstructured":"Moran S, O'Keefe M, Hartnett C, Lanigan B, Murphy J, Donoghue V. Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity. Acta Ophthalmol. 2014;92:e496\u20137.","journal-title":"Acta Ophthalmol"},{"key":"685_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603\u201315.","journal-title":"N Engl J Med"},{"key":"685_CR14","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1097\/IAE.0b013e318169faee","volume":"28","author":"R Axer-Siegel","year":"2008","unstructured":"Axer-Siegel R, Maharshak I, Snir M, Friling R, Ehrlich R, Sherf I, et al. Diode laser treatment of retinopathy of prematurity: anatomical and refractive outcomes. Retina. 2008;28:839\u201346.","journal-title":"Retina"},{"key":"685_CR15","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/eye.2014.172","volume":"28","author":"YH Chen","year":"2014","unstructured":"Chen YH, Chen SN, Lien RI, Shih CP, Chao AN, Chen KJ, et al. Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes. Eye (Lond). 2014;28:1080\u20136. quiz 1087","journal-title":"Eye (Lond)"},{"key":"685_CR16","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.ajo.2013.01.014","volume":"155","author":"BC Harder","year":"2013","unstructured":"Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jendritza B, Jonas JB. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol. 2013;155:1119\u201324. e1111","journal-title":"Am J Ophthalmol"},{"key":"685_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jaapos.2011.11.002","volume":"16","author":"RL Avery","year":"2012","unstructured":"Avery RL. Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both? J AAPOS. 2012;16:2\u20134.","journal-title":"J AAPOS."},{"key":"685_CR18","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/j.1600-0420.2007.01106.x","volume":"86","author":"R dell \u2019Omo","year":"2008","unstructured":"dell \u2019Omo R, Kulkarni A, Franks WA. Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity. Acta Ophthalmol. 2008;86:698\u2013700.","journal-title":"Acta Ophthalmol"},{"key":"685_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","volume":"118","author":"WC Wu","year":"2011","unstructured":"Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan. Ophthalmology. 2011;118:176\u201383.","journal-title":"Ophthalmology"},{"key":"685_CR20","first-page":"e123","volume":"3","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med. 2009;3:e123\u201330.","journal-title":"Open Med"},{"issue":"4","key":"685_CR21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.injury.2006.02.001","volume":"37","author":"BA Petrisor","year":"2006","unstructured":"Petrisor BA, Keating J, Schemitsch E. Grading the evidence: levels of evidence and grades of recommendation. Injury. 2006;37(4):321\u20137.","journal-title":"Injury"},{"key":"685_CR22","volume-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane collaboration","author":"J Higgins","year":"2011","unstructured":"Higgins J, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane collaboration,"},{"key":"685_CR23","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"685_CR24","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","volume":"121","author":"D Lepore","year":"2014","unstructured":"Lepore D, Quinn GE, Molle F, Baldascino A, Orazi L, Sammartino M, et al. Intravitreal Bevacizumab versus Laser Treatment in Type 1 Retinopathy of Prematurity. Ophthalmology. 2014;121:2212\u20139.","journal-title":"Ophthalmology"},{"issue":"6","key":"685_CR25","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1111\/aos.13008","volume":"94","author":"R Karkhaneh","year":"2016","unstructured":"Karkhaneh R, Khodabande A, Riazi-Eafahani M, Roohipoor R, Ghassemi F, Imani M, et al. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity. Acta Ophthalmol. 2016;94(6):e417\u201320.","journal-title":"Acta Ophthalmol"},{"issue":"8","key":"685_CR26","doi-asserted-by":"publisher","first-page":"e744","DOI":"10.1111\/aos.13069","volume":"94","author":"JM Walz","year":"2016","unstructured":"Walz JM, Bemme S, Pielen A, Aisenbrey S, Breuss H, Alex AF, et al. The German ROP registry: data from 90 infants treated for retinopathy of prematurity. Acta Ophthalmol. 2016;94(8):e744\u2013e752.","journal-title":"Acta Ophthalmol"},{"issue":"9","key":"685_CR27","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","volume":"123","author":"HA Mintz-Hittner","year":"2016","unstructured":"Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical Management of Recurrent Retinopathy of prematurity after Intravitreal Bevacizumab Monotherapy. Ophthalmology. 2016;123(9):1845\u201355.","journal-title":"Ophthalmology"},{"issue":"1","key":"685_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","volume":"37","author":"B Lorenz","year":"2017","unstructured":"Lorenz B, Stieger K, Jager M, Mais C, Stieger S, Andrassi-Darida M. Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal Fluorescein angiographic study. Retina. 2017;37(1):97\u2013111.","journal-title":"Retina"},{"key":"685_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000316134","volume":"45","author":"N Xiang","year":"2011","unstructured":"Xiang N, Zhao MJ, Li XY, Zheng HH, Li GG, Li B. Redundant mechanisms for vascular growth factors in retinopathy of prematurity in vitro. Ophthalmic Res. 2011;45:92\u2013101.","journal-title":"Ophthalmic Res"},{"key":"685_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000439182","volume":"234","author":"HK Kuo","year":"2015","unstructured":"Kuo HK, Sun IT, Chung MY, Chen YH. Refractive error in patients with retinopathy of prematurity after laser photocoagulation or Bevacizumab Monotherapy. Ophthalmologica. 2015;234:211\u20137.","journal-title":"Ophthalmologica"},{"key":"685_CR31","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.earlhumdev.2012.09.019","volume":"88","author":"HA Mintz-Hittner","year":"2012","unstructured":"Mintz-Hittner HA. Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors. Early Hum Dev. 2012;88:937\u201341.","journal-title":"Early Hum Dev"},{"key":"685_CR32","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130:1000\u20136.","journal-title":"Arch Ophthalmol"},{"key":"685_CR33","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1097\/01.iae.0000244293.94251.20","volume":"26","author":"BR Hurley","year":"2006","unstructured":"Hurley BR, JA MN, Fineman MS, Ho AC, Tasman W, Kaiser RS, et al. Laser treatment for retinopathy of prematurity: evolution in treatment technique over 15 years. Retina. 2006;26:S16\u20137.","journal-title":"Retina"},{"key":"685_CR34","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/OPX.0000000000000533","volume":"92","author":"L Ruan","year":"2015","unstructured":"Ruan L, Shan HD, Liu XZ, Huang X. Refractive status of Chinese with laser-treated retinopathy of prematurity. Optom Vis Sci. 2015;92:S3\u20139.","journal-title":"Optom Vis Sci"},{"key":"685_CR35","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.2147\/OPTH.S84077","volume":"9","author":"PH Nguyen","year":"2015","unstructured":"Nguyen PH, Catt C, Nguyen TX, Pham VT. Refractive outcome of prethreshold retinopathy of prematurity treated by diode laser: follow-up at 5 years. Clin Ophthalmol. 2015;9:1753\u20138.","journal-title":"Clin Ophthalmol"},{"key":"685_CR36","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1097\/OPX.0b013e3182279cfa","volume":"88","author":"EL Smith 3rd","year":"2011","unstructured":"Smith EL 3rd. Prentice award lecture 2010: a case for peripheral optical treatment strategies for myopia. Optom Vis Sci. 2011;88:1029\u201344.","journal-title":"Optom Vis Sci"},{"key":"685_CR37","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014;132:1327\u201333.","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"685_CR38","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3109\/02713683.2015.1084643","volume":"41","author":"Z Yi","year":"2016","unstructured":"Yi Z, Su Y, Zhou Y, Zheng H, Ye M, Xu Y, et al. Effects of Intravitreal Ranibizumab in the treatment of retinopathy of prematurity in Chinese infants. Curr Eye Res. 2016;41(8):1092\u20137.","journal-title":"Curr Eye Res"},{"key":"685_CR39","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jaapos.2006.05.005","volume":"10","author":"ML EM","year":"2006","unstructured":"EM ML, O'Keefe M, SF ML, Lanigan BM. Long-term refractive and biometric outcomes following diode laser therapy for retinopathy of prematurity. J AAPOS. 2006;10:454\u20139.","journal-title":"J AAPOS"},{"key":"685_CR40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S0161-6420(92)31968-2","volume":"99","author":"GE Quinn","year":"1992","unstructured":"Quinn GE, Dobson V, Repka MX, Reynolds J, Kivlin J, Davis B, et al. Development of myopia in infants with birth weights less than 1251 grams. The Cryotherapy for retinopathy of prematurity cooperative group. Ophthalmology. 1992;99:329\u201340.","journal-title":"Ophthalmology"},{"key":"685_CR41","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S0161-6420(01)01015-6","volume":"109","author":"BP Connolly","year":"2002","unstructured":"Connolly BP, Ng EY, JA MN, Regillo CD, Vander JF, Tasman W. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome. Ophthalmology. 2002;109:936\u201341.","journal-title":"Ophthalmology"},{"key":"685_CR42","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855\u20139.","journal-title":"Ophthalmology"},{"key":"685_CR43","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3928\/0191-3913-20070301-10","volume":"44","author":"E McLoone","year":"2007","unstructured":"McLoone E, O\u2019Keefe M, McLoone S, Lanigan B. Effect Of diode laser retinal ablative therapy for threshold retinopathy of prematurity on the visual field: results of goldmann perimetry at a mean age of 11 years. J Pediatr Ophthalmol Strabismus. 2007;44:170\u20133.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"685_CR44","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","volume":"33","author":"MA Martinez-Castellanos","year":"2013","unstructured":"Martinez-Castellanos MA, Schwartz S, Hernandez-Rojas ML, Kon-Jara VA, Garcia-Aguirre G, Guerrero-Naranjo JL, et al. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Retina. 2013;33:329\u201338.","journal-title":"Retina"},{"key":"685_CR45","doi-asserted-by":"publisher","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","volume":"11","author":"R Lien","year":"2016","unstructured":"Lien R, Yu MH, Hsu KH, Liao PJ, Chen YP, Lai CC, et al. Neurodevelopmental outcomes in infants with retinopathy of prematurity and Bevacizumab treatment. PLoS One. 2016;11:e0148019.","journal-title":"PLoS One"},{"issue":"4","key":"685_CR46","doi-asserted-by":"publisher","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","volume":"137","author":"J Morin","year":"2016","unstructured":"Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard MN, et al. Neurodevelopmental outcomes following Bevacizumab injections for retinopathy of prematurity. Pediatrics. 2016;137(4):e20153218.","journal-title":"Pediatrics"},{"key":"685_CR47","first-page":"395","volume":"105","author":"A Gotz-Wieckowska","year":"2003","unstructured":"Gotz-Wieckowska A, Kociecki J, Burchardt-Kroll E, Gadzinowski J. The results of diode treatment of active phase of retinopathy of prematurity. Klin Ocz. 2003;105:395\u20137.","journal-title":"Klin Ocz"},{"key":"685_CR48","first-page":"340","volume":"78","author":"MK Erol","year":"2015","unstructured":"Erol MK, Coban DT, Sari ES, Bilgin AB, Dogan B, Ozdemir O, et al. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arq Bras Oftalmol. 2015;78:340\u20133.","journal-title":"Arq Bras Oftalmol"},{"key":"685_CR49","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","volume":"35","author":"SN Chen","year":"2015","unstructured":"Chen SN, Lian I, Hwang YC, Chen YH, Chang YC, Lee KH, et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Retina. 2015;35:667\u201374.","journal-title":"Retina"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-018-0685-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T19:15:38Z","timestamp":1570648538000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-018-0685-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,30]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["685"],"URL":"https:\/\/doi.org\/10.1186\/s12886-018-0685-6","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,30]]},"assertion":[{"value":"3 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"19"}}